Pharma BD Deal Intelligence
A slow-burn vindication: Pfizer's $95M equity bet on Valneva survived a February 2023 setback that discontinued roughly half the U.S. VALOR participants over site-level GCP violations, before Phase 3 efficacy of 73.2% arrived in 2026.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer expanded its Lyme disease vaccine partnership with Valneva on Wednesday, taking an 8.1% equity stake in the French biotech and restructuring milestones…
Pfizer is putting fresh capital into the troubled Lyme disease vaccine space with a 95 million dollar equity investment in Valneva, signaling commitment to…
Pfizer is making a fresh equity investment in Valneva worth approximately 90.5 million euros to support advancement of VLA15, the only Lyme disease vaccine…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Pfizer and Valneva updated their Lyme disease vaccine collaboration on June 22, 2022: Pfizer made a EUR90.5M (~$95M) equity investment for an 8.1% stake in Valneva, with up to $168M in remaining development/early-commercialization milestones, up to $100M in cumulative sales milestones, and tiered 14%-22% royalties, alongside initiation of the Phase 3 VALOR study (VLA15) in Q3 2022. The program then weathered a major setback: on February 17, 2023 Pfizer discontinued roughly half of the U.S. participants after Good Clinical Practice violations were found at a third-party clinical-trial site operator (not a vaccine safety or adverse-event issue). VALOR continued, and on March 22-23, 2026 Pfizer and Valneva reported strong Phase 3 efficacy for the six-valent OspA-based candidate (now PF-07307405 / LB6V, formerly VLA15): 73.2% efficacy from 28 days post-dose 4 (season 2) and 74.8% from 1 day post-dose 4, with the vaccine well tolerated and no safety concerns identified. Pfizer stated it is planning submissions to regulatory authorities (FDA/EMA). A positive readout materially de-risks what would be the first Lyme disease vaccine since LYMErix was withdrawn in 2002.
476K US cases/yr · $1.0B Estimated U.S. Lyme vaccine peak revenue opportunity · ~30,000-40,000 Annual cases formally reported to CDC surveillance
Lyme disease is the most common vector-borne illness in the United States, caused by Borrelia burgdorferi (and related Borrelia species) and transmitted via Ixodes scapularis (deer tick) and Ixodes pacificus bites. The CDC estimates approximately 476,000 Americans are diagnosed and treated for Lyme disease annually, based on insurance claims data, though only about 30,000-40,000 cases are formally reported through public health surveillance. Geographic concentration is heavy in the Northeast (Connecticut, New York, Pennsylvania, New Jersey, Massachusetts), upper Midwest (Wisconsin, Minnesota), and parts of Northern California, with climate-driven tick range expansion increasing endemic exposure annually. Untreated infection can progress from erythema migrans to disseminated arthritis, carditis, and neuroborreliosis. There is currently no licensed Lyme vaccine on the U.S. market — GSK's LYMErix was withdrawn in 2002 amid weak commercial uptake and class-action concerns despite being safe and effective. The unmet prevention need is acute, the addressable population is large in endemic states, and ACIP/CDC engagement on a successor vaccine is well-established. Pricing precedent for adult travel/recreational vaccines suggests $150-250 per series at WAC.
The Lyme disease vaccine landscape is effectively a single-asset competitive picture. The Pfizer/Valneva VLA15 program is a multivalent recombinant OspA-based vaccine targeting six serotypes covering Borrelia strains relevant in North America and Europe — currently in Phase 3 (VALOR study) and the only candidate in pivotal development. Historical context includes GSK's LYMErix (monovalent OspA), approved by FDA in 1998 and withdrawn voluntarily in 2002 due to commercial underperformance and litigation pressure rather than safety failure. Earlier-stage competitors include MassBiologics' Lyme PrEP monoclonal antibody (anti-OspA mAb passive immunization, Phase 1/2) and academic programs at Yale and Stony Brook exploring alternative antigen approaches. No mRNA Lyme vaccine has progressed publicly into late-stage development. The competitive moat for VLA15 is the combination of pivotal-stage lead time (5-7 years ahead of any competing vaccine candidate), multivalent design covering both U.S. and European serotypes, and the established Pfizer vaccine commercial infrastructure post-COVID. Pricing precedent for adult travel and adult booster vaccines suggests a $150-250 per dose WAC range, with peak commercial assumptions of $700-1,000M annual revenue if ACIP delivers a universal endemic-state recommendation.
Pfizer discontinued approximately half of the U.S. participants in the Phase 3 VALOR Lyme vaccine trial following Good Clinical Practice violations at a third-party clinical-trial site operator. The action was not related to vaccine safety or any participant-reported adverse event; the trial continued.
Pfizer and Valneva reported strong Phase 3 VALOR efficacy for PF-07307405 (LB6V, formerly VLA15): 73.2% from 28 days post-dose 4 (season 2) and 74.8% from 1 day post-dose 4 in preventing confirmed Lyme disease in participants aged 5+. Well tolerated, no safety concerns. Pfizer stated it is planning submissions to regulatory authorities (FDA/EMA), positioning VLA15 to become the first Lyme vaccine since LYMErix (withdrawn 2002).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Valneva SE (VLA15 collaboration update) (this deal) | 2022 | $363M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2022 deals · Pfizer Inc. deals · Infectious Disease deals